Hongene Launches Operations at its New mRNA CDMO GMP Facility
Hongene launches operations at its new mRNA CDMO GMP facility, ensuring efficient, high-quality production of mRNA therapeutics and vaccines.
The new facility consists of more than 30,000 sq. ft. of laboratory and GMP manufacturing space, equipped with advanced technology and processes, which support the production of non-GMP products for formulation development and toxicology studies, as well as GMP products for early and late-stage clinical trials.
As the facility commenced operation, Hongene was proud to become the first company in China with the capability of mRNA production, offering comprehensive mRNA CDMO services for the development and manufacturing of high-quality and cost-effective RNA medicines to support customers' journeys from discovery to commercialization.